UVA researcher Blandine Baffert, working in the lab of UVA Health’s Sanja Arandjelovic and collaborating with researchers in ...

SAN FRANCISCO--(BUSINESS WIRE)--The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Sanofi will contribute the first ...

Scleroderma is a chronic autoimmune disease of women. Over time, people living with scleroderma develop progressive and irreversible scarring. Scarring, called fibrosis, affects the lungs, heart and ...

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

Jennene's swollen hands and feet during a bike ride were the first sign of scleroderma - a rare autoimmune condition.

Q: Would you define scleroderma? What are the early symptoms? Are there any tests to diagnose it? A: Scleroderma, or hard skin, isn't a common disorder. In a metropolitan area the size of St. Louis, ...

The University of Michigan John Varga Lab, in collaboration with the Mayo Clinic and Northwestern researchers, published an article last year suggesting that a heavy-chain monoclonal antibody, Ab68, ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...

What is the latest research on scleroderma? Find out in this collection of recent MEDLINE abstracts compiled by the editors at Medscape Nurses. Acute and chronic renal diseases remain common ...

Following the 2017 American College of Rheumatology (ACR) Annual Meeting—held in San Diego, California, November 3-8—Medscape spoke with Hospital for Special Surgery rheumatologists Dr Robert F.